In breast cancer cells, SGLT1 overexpression drives glucose uptake and lactic acid secretion, which promotes macrophage polarization to M2-like TAMs that then activate the EGFR/PI3K/Akt/SGLT1 signaling pathway in the tumor cells to induce resistance to tamoxifen (66). Here, SLC5A1 is linked to breast cancer.